BLACKSTONE VENTURES INC. Inactive Instrument
Blackstone Ventures Inc. Stock Toronto S.E.
Equities
BLV
CA0925831038
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
||
| - CAD | - |
|
| Sales 2019 | 2.19M 3.01M | Sales 2020 | 2.46M 3.39M | Capitalization | 4.74M 6.52M |
|---|---|---|---|---|---|
| Net income 2019 | -1M -1.37M | Net income 2020 | -1M -1.37M | EV / Sales 2019 | 1.74 x |
| Net Debt 2019 | 2.12M 2.91M | Net Debt 2020 | 3.08M 4.23M | EV / Sales 2020 | 3.17 x |
| P/E ratio 2019 |
-1.67
x | P/E ratio 2020 |
-2.56
x | Employees | - |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 79.69% |
More Fundamentals
* Assessed data
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Companyâs products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Companyâs stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.67% | 125B | |
| -10.82% | 10.51B | |
| -5.04% | 8.65B | |
| +21.40% | 4.77B | |
| +7.58% | 3.42B | |
| -0.34% | 3.03B | |
| -13.27% | 1.97B | |
| -12.45% | 1.95B | |
| -30.28% | 1.62B |
- Stock Market
- Equities
- LBLTF Stock
- BLV Stock
